77 related articles for article (PubMed ID: 1997945)
1. Walking along human c-myc mRNA with antisense oligodeoxynucleotides: maximum efficacy at the 5' cap region.
Bacon TA; Wickstrom E
Oncogene Res; 1991; 6(1):13-9. PubMed ID: 1997945
[TBL] [Abstract][Full Text] [Related]
2. Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells.
Daaka Y; Wickstrom E
Oncogene Res; 1990; 5(4):267-75. PubMed ID: 2204019
[TBL] [Abstract][Full Text] [Related]
3. Structure of translation initiation region of c-myc mRNA and thermostability of the c-myc mRNA/antisense ODN complex.
Tanaka T; Kurihara Y; Sakamoto T; Furusawa M; Kobayashi A; Katahira M; Takeuchi K; Sugimoto N; Uesugi S
Nucleic Acids Symp Ser; 1995; (34):135-6. PubMed ID: 8841589
[TBL] [Abstract][Full Text] [Related]
4. Quantifying c-myc expression in c-myc antisense phosphorothioate oligodeoxynucleotide-treated leukemic and colon cancer cell lines.
Li BD; Budnick RM; Russo CA; Anderson GR; Stewart CC
J Surg Res; 1995 Oct; 59(4):485-92. PubMed ID: 7564322
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides.
Bennett MR; Anglin S; McEwan JR; Jagoe R; Newby AC; Evan GI
J Clin Invest; 1994 Feb; 93(2):820-8. PubMed ID: 8113414
[TBL] [Abstract][Full Text] [Related]
6. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers.
Chavany C; Connell Y; Neckers L
Mol Pharmacol; 1995 Oct; 48(4):738-46. PubMed ID: 7476902
[TBL] [Abstract][Full Text] [Related]
7. Reduction of cisplatin cytotoxicity on human lung cancer cell lines with N-myc amplification by pretreatment with N-myc antisense oligodeoxynucleotides.
Mizushima Y; Kashii T; Kobayashi M
Anticancer Res; 1995; 15(1):37-43. PubMed ID: 7733638
[TBL] [Abstract][Full Text] [Related]
8. In vitro mutational and inhibitory analysis of the cis-acting translational elements within the 5' untranslated region of coxsackievirus B3: potential targets for antiviral action of antisense oligomers.
Yang D; Wilson JE; Anderson DR; Bohunek L; Cordeiro C; Kandolf R; McManus BM
Virology; 1997 Feb; 228(1):63-73. PubMed ID: 9024810
[TBL] [Abstract][Full Text] [Related]
9. Translation of the human c-myc P0 tricistronic mRNA involves two independent internal ribosome entry sites.
Nanbru C; Prats AC; Droogmans L; Defrance P; Huez G; Kruys V
Oncogene; 2001 Jul; 20(31):4270-80. PubMed ID: 11464293
[TBL] [Abstract][Full Text] [Related]
10. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1.
Heikkila R; Schwab G; Wickstrom E; Loke SL; Pluznik DH; Watt R; Neckers LM
Nature; 1987 Jul 30-Aug 5; 328(6129):445-9. PubMed ID: 3302722
[TBL] [Abstract][Full Text] [Related]
11. [Transcription of antisense RNA for the human c-myc gene].
Shliakhova LN; Itkes AV; Chernov BK; Kiselev LL
Mol Biol (Mosk); 1994; 28(4):909-17. PubMed ID: 7990819
[TBL] [Abstract][Full Text] [Related]
12. Daily addition of an anti-c-myc DNA oligomer induces granulocytic differentiation of human promyelocytic leukemia HL-60 cells in both serum-containing and serum-free media.
Bacon TA; Wickstrom E
Oncogene Res; 1991; 6(1):21-32. PubMed ID: 1997946
[TBL] [Abstract][Full Text] [Related]
13. C-myc expression affects proliferation but not terminal differentiation or survival of explanted erythroid progenitor cells.
Bondurant MC; Yamashita T; Muta K; Krantz SB; Koury MJ
J Cell Physiol; 1996 Aug; 168(2):255-63. PubMed ID: 8707861
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
15. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells.
Kimura S; Maekawa T; Hirakawa K; Murakami A; Abe T
Cancer Res; 1995 Mar; 55(6):1379-84. PubMed ID: 7882339
[TBL] [Abstract][Full Text] [Related]
16. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
[TBL] [Abstract][Full Text] [Related]
17. Phosphorothioated antisense c-myc oligonucleotide inhibits the growth of human colon carcinoma cells.
Yu BW; Nguyen D; Anderson S; Allegra CA
Anticancer Res; 1997; 17(6D):4407-13. PubMed ID: 9494542
[TBL] [Abstract][Full Text] [Related]
18. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
19. Mapping and characterization of the minimal internal ribosome entry segment in the human c-myc mRNA 5' untranslated region.
Cencig S; Nanbru C; Le SY; Gueydan C; Huez G; Kruys V
Oncogene; 2004 Jan; 23(1):267-77. PubMed ID: 14712232
[TBL] [Abstract][Full Text] [Related]
20. Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotides.
Giles RV; Tidd DM
Anticancer Drug Des; 1992 Feb; 7(1):37-48. PubMed ID: 1311929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
